Filing Flows › Biotricity (BTCY) › Q3 FY25
Biotricity (BTCY) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Feb 19, 2025
Biotricity (BTCY) reported revenue of $3.6M for the third quarter fiscal 2025 (Q3 FY25), +22% from a year earlier and +11% from the quarter before. Operating margin was -4.7%, net loss $1.2M (34.0% of revenue).
Biotricity, Q3 FY25: revenue $3.6M (+22% year over year), operating margin -4.7%, net loss $1.2M, operating cash flow −$88K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.6M | +11% | +22% |
| Operating profit | −$169K | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | −$88K | — | — |
What changed
Revenue was $3.6M in Q3 FY25, up 22% year over year and up 11% from the previous quarter. Technology Fees was the largest line at 94% of revenue. Technology Fees added $606K year over year (up 22%), 94% of the total change.
Gross margin was 76.4%, up 3.4 points from a year earlier. Operating costs exceeded revenue by $169K, an operating margin of -4.7%. Operating expenses fell 15% while revenue rose 22%. The fastest-growing cost line was Research & development (+22%). The quarter ended with a net loss of $1.2M, narrower than the previous quarter's $1.6M loss. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was −$88K. Non-cash charges added back $1K of depreciation and $57K of share-based compensation. Working capital and other items added $1.1M.
Questions
What was Biotricity's revenue in the third quarter fiscal 2025?
Biotricity (BTCY) reported revenue of $3.6M for the third quarter fiscal 2025 (Q3 FY25), +22% from a year earlier and +11% from the quarter before.
Was Biotricity profitable in the third quarter fiscal 2025?
Operating loss was $169K (-4.7% of revenue) and net loss $1.2M.
Source: Biotricity 10-Q on SEC EDGAR.